The role of miR ‐335‐5p in the redifferentiation of BRAF p. V600E thyroid cancers
Molecular Oncology · 2026-11 · 20 (11) · 2955-2973
DOI: 10.1002/1878-0261.70181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 22.06.2026. Verfasst von Valeria Pecce und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational and Precision Medicine, Sapienza University of Rome, Italy. Hauptthemen laut MEDLINE: MicroRNAs, Proto-Oncogene Proteins B-raf, Thyroid Neoplasms, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sapienza Università di Roma, Ministero dell'Università e della Ricerca.
Abstract (Originalsprache)
The BRAF p.V600E mutation activates the RAS/BRAF/MEK/ERK pathway, leading to cancer cell dedifferentiation and uncontrolled growth. In radioiodine‐refractory thyroid cancers, MEK and/or BRAF inhibitors can induce redifferentiation, resensitizing tumors to radioiodine. However, compensatory mechanisms limit this efficacy. We used the SWitchMiner software to identify a small pool of regulatory genes, called switch genes, critically associated with drastic changes in cell phenotypes, using TCGA transcriptomic data from BRAF ‐mutant papillary thyroid carcinoma and normal thyroid tissues, which highlighted miR‐335‐5p. Restoring miR‐335‐5p in thyroid cancer cell lines harboring the BRAF mutation increased expression of thyroid‐specific genes and proteins, especially in well‐differentiated cell lines, with enhanced sodium‐iodide symporter localization and iodine uptake confirmed in organoids. Due to the connection between thyroid‐specific and EMT‐related genes in the protein–protein interaction network, we examined how miR‐335‐5p overexpression affects EMT pathway genes that modulate thyroid‐specific genes and Kinase Inhibitor (KI) resistance. miR‐335‐5p inhibited the expression of nearly all analyzed genes in less‐differentiated thyroid cell lines. Thus, miR‐335‐5p may be a viable therapeutic target to restore radioiodine avidity in BRAF ‐mutant metastatic thyroid cancer and enhance KI treatment redifferentiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational and Precision Medicine, Sapienza University of Rome, Italy.
- Department for the Promotion of Human Science and Quality of Life, San Raffaele Roma University, Rome, Italy.
- Department of Computer, Control, and Management Engineering "Antonio Ruberti", Sapienza University of Rome, Italy.
- Department of Oncology, Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy.
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, Italy.
ORCID-Profile: Valeria Pecce
Förderung
- Sapienza Università di Roma
- Ministero dell'Università e della Ricerca
Zitieren
APA
Pecce, V., Bini, S., Sponziello, M., Grani, G., Fiscon, G., Paci, P., Farina, L., Falcone, R., Maggisano, V., Filetti, S., Durante, C., & Verrienti, A. (2026). The role of miR ‐335‐5p in the redifferentiation of BRAF p. V600E thyroid cancers. Molecular Oncology, 20(11), 2955-2973. https://doi.org/10.1002/1878-0261.70181
Vancouver
Pecce V, Bini S, Sponziello M, Grani G, Fiscon G, Paci P, et al. The role of miR ‐335‐5p in the redifferentiation of BRAF p. V600E thyroid cancers. Molecular Oncology. 2026;20(11):2955-2973. doi:10.1002/1878-0261.70181
BibTeX
@article{Pecce2026,
author = {Pecce, Valeria and Bini, Simone and Sponziello, Marialuisa and Grani, Giorgio and Fiscon, Giulia and Paci, Paola and Farina, Lorenzo and Falcone, Rosa and Maggisano, Valentina and Filetti, Sebastiano and Durante, Cosimo and Verrienti, Antonella},
title = {The role of miR ‐335‐5p in the redifferentiation of BRAF p. V600E thyroid cancers},
journal = {Molecular Oncology},
year = {2026},
volume = {20},
number = {11},
pages = {2955--2973},
doi = {10.1002/1878-0261.70181}
}
EUVIMED